. Author manuscript; available in PMC: 2015 Dec 20.

Published in final edited form as: J Urol. 2014 Aug 9;192(6):1642–1648. doi: 10.1016/j.juro.2014.08.002

Table 2.

Results of standard 12-core and MRI/US fusion targeted biopsies by PSA cutoff

PSA ng/ml Cutoff (targeted biopsy result)	No. 12-Core Biopsy Result/Total No. (%)
PSA ng/ml Cutoff (targeted biopsy result)	No Ca	Clinically Insignificant Ca	Clinically Significant Ca
0–Less than 2.5:
No Ca	45/81^*	8/36	(22.2)^* 0^*
Clinically insignificant Ca	10/36 (27.8)^*	16/36 (44.4)^*	0^*
Clinically significant Ca	1/36 (2.8)^†	0^*	1/36 (2.8)^*
2.5–Less than 4:
No Ca	56/131^*	19/75 (25.3)^*	1/75 (1.3)^†
Clinically insignificant Ca	11/75 (14.7)^*	37/75 (49.3)^*	2/75 (2.7)^†
Clinically significant Ca	0^*	0^*	5/75 (6.7)^*
4–10:
No Ca	229/513^*	54/284 (19.0)^*	1/284 (0.4)^†
Clinically insignificant Ca	35/284 (12.3)^*	122/284 (43.0)^*	7/284 (2.5)^†
Clinically significant Ca	6/284 (2.1)^†	22/284 (7.7)^†	37/284 (13.0)^*
Greater than 10:
No Ca	109/278^*	17/169 (10.1)^*	3/169 (1.8)^†
Clinically insignificant Ca	13/169 (7.7)^*	30/169 (17.8)^*	5/169 (3.0)^†
Clinically significant Ca	19/169 (11.2)^†	22/169 (13.0)^†	60/169 (35.5)^*
Overall:
No Ca	439/1,003^*	98/564 (17.4)^*	5/564 (0.9)^†
Clinically insignificant Ca	69/564 (12.2)^*	205/564 (36.3)^*	14/564 (2.5)^†
Clinically significant Ca	26/564 (4.6)^†	44/564 (7.8)^†	103/564 (18.3)^*

Biopsy methods concordant or missed clinically insignificant disease, defined as Gleason score 7 (3 + 4) or less.

^†

Biopsy method under graded or missed clinically significant disease, defined as Gleason score 7 (4 + 3) or greater.